Log In
Print
BCIQ
Print
Print this Print this
 

VX-509

  Manage Alerts
Collapse Summary General Information
Company Vertex Pharmaceuticals Inc.
DescriptionOral Janus kinase 3 (JAK-3) inhibitor
Molecular Target Janus kinase-3 (JAK-3)
Mechanism of ActionJanus kinase-3 (JAK-3) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II/III
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat active rheumatoid arthritis (RA); Treat moderate to severe rheumatoid arthritis (RA)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today